Navigation Links
Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
Date:5/29/2009

UPMC Mercy hospital has cuccessfully implemented the TraumaCad digital templating solution from Orthocrat. Using TraumaCad, UPMC Mercy's orthopedic surgeons can preoperatively plan their surgeries digitally, from anywhere within the UPMC enterprise.

Columbia, MD (PRWEB) May 29, 2009 -- Orthocrat, Ltd. announced today that UPMC Mercy, part of the UPMC global health enterprise, has successfully implemented the TraumaCad digital orthopedic templating solution.

TraumaCad allows UPMC Mercy's orthopedic surgeons to preoperatively plan their surgeries from anywhere, by accessing their patients' images using UPMC's enterprise-wide digital imaging (PACS) system.

Rasu B. Shrestha, MD, MBA, UPMC's Medical Director for Digital Imaging Informatics, explains, "Our orthopedic surgeons at UPMC Mercy can now digitally plan their surgeries at a time that is convenient to them, with complete access to all necessary x-rays and advanced planning tools. This allows the surgeon to more accurately predict the type and size of prosthetic implants, and is proving to be a clinical advantage."

"We are proud to have UPMC Mercy as our customer," says Zeev Glozman, Orthocrat's CEO. "In the coming months, we look forward to introducing ever more advanced clinical capabilities, such as our auto-hip templating and our advanced deformity-correction software, to UPMC's surgeons."

Dr. Shrestha adds, "The TraumaCad implementation has gone very smoothly, and we look forward to seeing increasing efficiencies for our orthopedic surgeons and benefits for our patients."

About Orthocrat
Orthocrat has a simple mission: To dramatically improve the orthopedic surgeon's workflow, so that more time can be spent with patients. TraumaCad, our flagship product, is installed at over 1,000 locations in ten countries, including hospitals, clinics and academic i
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. George Washington University Hospital Purchases Orthocrats TraumaCad(TM) for Orthopedic Preoperative Planning
2. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
3. Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better
4. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. Medivation Announces Pricing of Public Offering
7. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
8. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
9. SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY
10. Accumetrics, Inc. Announces European Distribution Channels for France, Austria, Switzerland, Netherlands, Belgium and Luxembourg
11. Oncothyreon announces closing of $11.1 million registered direct financing
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):The pitch of blue whale songs is declining around the world, scientists discover 2The pitch of blue whale songs is declining around the world, scientists discover 3MSU research may lead to new ways to control honeybee parasite 2KV Pharmaceutical Company Purdue Pharma L P Settle OxyContin 28R 29 Dispute 48392 1KV Pharmaceutical Company Purdue Pharma L P Settle OxyContin 28R 29 Dispute 48392 2KV Pharmaceutical Company Purdue Pharma L P Settle OxyContin 28R 29 Dispute 48392 3KV Pharmaceutical Company Purdue Pharma L P Settle OxyContin 28R 29 Dispute 48392 4KV Pharmaceutical Company Purdue Pharma L P Settle OxyContin 28R 29 Dispute 48392 5KV Pharmaceutical Company Purdue Pharma L P Settle OxyContin 28R 29 Dispute 48392 6Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 1Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 2Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 3Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 4Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 5Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 6Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 7Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 8Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 9Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 10Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 11Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 12Landmark Study Published in New England Journal of Medicine 48389 1Landmark Study Published in New England Journal of Medicine 48389 2Landmark Study Published in New England Journal of Medicine 48389 3